Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

538
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
538
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
521

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis.

Asian Pacific journal of cancer prevention : APJCP·2026
Same author

Association of Preoperative Inflammatory Markers With Preoperative Anxiety and Emergence Agitation in Children.

Paediatric anaesthesia·2026
Same author

The Correlation Between PD-L1 Expression in Metaplastic Breast Cancer and Clinical-Pathological Features and Prognosis.

Medicina (Kaunas, Lithuania)·2026
Same author

Experiences of Ageism Among Older Adults Registered with a Family Health Centre: A Mixed-Methods Research Study.

Healthcare (Basel, Switzerland)·2026
Same author

Effects of Subconjunctival Bevacizumab and Ranibizumab on Corneal and Systemic Oxidative Stress Biomarkers in an Alkali Injury Model.

Life (Basel, Switzerland)·2026
Same author

Determinants of mortality following intertrochanteric fractures, comorbidities versus reduction quality: retrospective cohort study.

Journal of orthopaedic surgery and research·2026

相关实验视频

Updated: Jan 13, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

在患有非酒精性脂肪肝疾病的预肥或肥胖个体中,虹膜素和氨酸的降低.

Cuma Mertoğlu1,2, Yaprak Şule Örek2, Bülent Albayrak3

  • 1Department of Medical Biochemistry, Faculty of Medicine, İnönü University, Malatya, Turkiye.

Turkish journal of medical sciences
|January 9, 2026
PubMed
概括

在患有非酒精性脂肪性肝病 (NAFLD) 的个体中,无论严重程度如何,血清中的虹膜素和氨酸水平都较低. 这些发现表明,这些激素在肥胖成年人中NAFLD的发展和进展中起着作用.

关键词:
非酒精性脂肪性肝病是非酒精性脂肪性肝病.亚德罗宾 (adropin) 是一种药物.异物原性指数是指异物原性指数.血液学参数 血液学参数虹膜是一种虹膜.

更多相关视频

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.7K

相关实验视频

Last Updated: Jan 13, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.6K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.7K

科学领域:

  • 代谢性疾病研究研究.
  • 肥胖中的荷尔蒙功能
  • 肝脏的健康和疾病.

背景情况:

  • 非酒精性脂肪肝 (NAFLD) 是一种代谢状况,经常与肥胖有关.
  • 虹膜素和氨酸是参与新陈代谢调节的激素.

研究的目的:

  • 为了研究预肥或肥胖的成年人中不同程度的NAFLD的血清虹膜素和氨酸水平.
  • 探索这些激素水平与NAFLD严重程度之间的关系.

主要方法:

  • 该研究包括89名参与者,分为四组:正常体重对照组,没有NAFLD的前肥胖/肥胖,以及1级或2-3级NAFLD的前肥胖/肥胖.
  • 通过ELISA进行了腹部超声波,人体测量评估和血清荷尔蒙水平的确定.

主要成果:

  • 与正常体重对照组相比,NAFLD患者 (1-3级) 的血清阿德罗宾和虹膜素水平显著降低.
  • 激素水平在NAFLD严重程度组之间没有显著差异 (1级与2-3级).
  • 在NAFLD组中观察到较高的动脉动脉生成指数和红细胞分布宽度.

结论:

  • 血清中阿德罗宾和虹膜素水平的降低与预肥和肥胖个体中NAFLD的存在有关.
  • 这些荷尔蒙变化可能会导致NAFLD的发展和恶化.
  • 需要进一步的研究来阐明具体的机制.